Cellino Appoints Chris Gibson to Board of Directors
Cellino Biotech has appointed Chris Gibson, Ph.D., to its Board of Directors. Gibson, the Co-Founder and CEO of Recursion (NASDAQ:RXDX), brings significant experience in AI-driven biotechnology and pharmaceutical partnerships. Under his leadership, Recursion has established partnerships with major companies like Roche/Genentech, Bayer, and NVIDIA, and is expecting 10 clinical readouts in the next 18 months following its proposed combination with Exscientia. Cellino's focus is on autonomous, closed biomanufacturing for personalized regenerative medicines, utilizing technologies including optical bioprocessing and image-guided co-pilots.
Cellino Biotech ha nominato Chris Gibson, Ph.D., nel suo Consiglio di Amministrazione. Gibson, co-fondatore e CEO di Recursion (NASDAQ:RXDX), porta una notevole esperienza nelle biotecnologie e nelle partnership farmaceutiche guidate dall'IA. Sotto la sua direzione, Recursion ha stabilito collaborazioni con grandi aziende come Roche/Genentech, Bayer e NVIDIA, e prevede 10 risultati clinici nei prossimi 18 mesi, a seguito della sua proposta di combinazione con Exscientia. Cellino si concentra sulla biomanifattura autonoma e chiusa per medicine rigenerative personalizzate, utilizzando tecnologie tra cui il bioprocessing ottico e i co-piloti guidati da immagini.
Cellino Biotech ha nombrado a Chris Gibson, Ph.D., en su Junta Directiva. Gibson, cofundador y CEO de Recursion (NASDAQ:RXDX), aporta una experiencia significativa en biotecnología impulsada por IA y asociaciones farmacéuticas. Bajo su liderazgo, Recursion ha establecido asociaciones con importantes empresas como Roche/Genentech, Bayer y NVIDIA, y espera 10 resultados clínicos en los próximos 18 meses tras su propuesta de combinación con Exscientia. El enfoque de Cellino está en la biomanufactura autónoma y cerrada para medicamentos regenerativos personalizados, utilizando tecnologías que incluyen procesamientos ópticos y copilotos guiados por imágenes.
Cellino Biotech는 Chris Gibson 박사를 이사회에 임명했습니다. Gibson은 Recursion (NASDAQ:RXDX)의 공동 설립자이자 CEO로, AI 기반 생명공학 및 제약 파트너십 분야에서 상당한 경험을 가지고 있습니다. 그의 리더십 아래, Recursion은 Roche/Genentech, Bayer, NVIDIA와 같은 주요 기업과 파트너십을 구축했으며, Exscientia와의 제안된 통합에 따라 향후 18개월 동안 10개의 임상 결과를 예상하고 있습니다. Cellino의 초점은 맞춤형 재생 의약품을 위한 자율 폐쇄형 생물제조에 있으며, 여기에는 광학 생물 가공 및 이미지 유도 조종사 기술이 포함됩니다.
Cellino Biotech a nommé Chris Gibson, Ph.D., à son Conseil d'Administration. Gibson, co-fondateur et PDG de Recursion (NASDAQ:RXDX), apporte une expérience significative dans les partenariats en biotechnologie et en pharmacie axés sur l'IA. Sous sa direction, Recursion a établi des partenariats avec de grandes entreprises telles que Roche/Genentech, Bayer et NVIDIA, et prévoit 10 résultats cliniques au cours des 18 prochains mois suite à sa proposition de combinaison avec Exscientia. L'objectif de Cellino est de se concentrer sur la biomanufacture autonome et fermée pour des médicaments régénératifs personnalisés, en utilisant des technologies comprenant le bioprocessing optique et des co-pilotes guidés par images.
Cellino Biotech hat Chris Gibson, Ph.D., in seinen Vorstand berufen. Gibson, Mitbegründer und CEO von Recursion (NASDAQ:RXDX), bringt umfassende Erfahrungen in der KI-gesteuerten Biotechnologie und pharmazeutischen Partnerschaften mit. Unter seiner Leitung hat Recursion Partnerschaften mit großen Unternehmen wie Roche/Genentech, Bayer und NVIDIA etabliert und erwartet in den nächsten 18 Monaten zehn klinische Ergebnisse im Anschluss an die vorgeschlagene Kombination mit Exscientia. Cellinos Fokus liegt auf autonomer, geschlossener Biomanufaktur für personalisierte regenerative Medikamente und nutzt Technologien wie optische Bioprozessierung und bildgeführte Co-Piloten.
- Addition of experienced biotech leader with proven track record in AI-driven drug discovery
- Strategic alignment with leader in pharmaceutical partnerships (Roche/Genentech, Bayer, NVIDIA)
- Access to expertise from Recursion's successful clinical development pipeline
- None.
Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion)
Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genentech, Bayer, and NVIDIA. Recursion’s recent proposed combination with Exscientia creates a robust AI-powered pipeline, with 10 clinical readouts expected in the next 18 months. Dr. Gibson also established the non-profit Recursion Foundation, which has incubated over a dozen companies and created a new generation of biotechnology founders, and personally mentors dozens of entrepreneurs to support the next wave of founder-CEOs.
“We are thrilled to welcome Chris to our board. As a seasoned founder and CEO, his hands-on experience and operational insights will be invaluable as we scale our team and vision for patient impact,” said Nabiha Saklayen, CEO & Co-Founder of Cellino. “The intersection of deep technology, biology, and medicine presents unprecedented opportunities and challenges. We are thrilled to have Chris’ experience on our board to provide Cellino with a perspective that is both visionary and deeply practical.”
“Cellino is driving the next wave of innovation in autonomous biomanufacturing,” said Gibson. “Cellino’s proprietary technology stack, including optical bioprocessing, closed cassettes, and image-guided co-pilots, has the potential to transform healthcare and bring potentially curative therapies to millions of patients. I look forward to working alongside Nabiha, the Cellino team, and the Board to make cell and tissue replacement therapies accessible to all.”
Autologous induced pluripotent stem cell-derived regenerative cell and tissue replacement therapies that utilize a patient’s own cells offer a promising avenue for addressing a variety of medical conditions. They minimize immune-related complications and are exceptionally well-suited to meet the needs of an aging and increasingly diverse patient population.
About Cellino
Cellino is building an ultra-scalable, autonomous, high precision biomanufacturing technology for personalized regenerative medicines. Learn more at www.cellinobio.com and follow Cellino on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024933617/en/
Media:
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Cellino Biotech, Inc.
FAQ
Who is the new board member appointed to Cellino Biotech?
What major partnerships has Chris Gibson led at Recursion (RXDX)?
How many clinical readouts is Recursion (RXDX) expecting following its combination with Exscientia?
